Inify Laboratories (INIFY) Q3 2025 earnings summary

Executive summary

• Achieved first gastrointestinal patient diagnoses, expanding beyond prostate cancer diagnostics.

• Revenue grew 76% year-over-year in Q3 2025, with strong sales momentum and ongoing customer acquisition.

• UK laboratory construction is progressing on schedule, targeting clinical launch in early 2026.

• Cash balance at period end was SEK 112 million, supporting continued investments and expansion.

Financial highlights

• Q3 2025 net sales reached SEK 4,991 thousand, up from SEK 2,833 thousand in Q3 2024.

• EBITDA for Q3 2025 was SEK -13,827 thousand, compared to SEK -10,968 thousand in Q3 2024.

• Net result for Q3 2025 was SEK -14,645 thousand, versus SEK -11,907 thousand in Q3 2024.

• Equity at period end was SEK 127.6 million, with an equity ratio of 83.1%.

• Cash flow for Q3 2025 was SEK -17.6 million, improved from SEK -33.2 million in Q3 2024.

Outlook and guidance

• Expecting gradual sales growth from gastrointestinal diagnostics, with more significant impact from 2026.

• UK operations on track for early 2026 launch, with advanced customer dialogues underway.

• Continued investments in expansion and technology development aligned with long-term vision.